Effect of chitosan on physicochemical properties of exenatide-loaded PLGA nanoparticles

Journal of Pharmaceutical Investigation

Volumn 43, Issue 6, 2013, Pages 489-497

  Park, Min Ho ^a   Baek, Jong Suep ^a   Lee, Cho A ^a   Cho, Cheong Weon ^a  

^a Chungnam National University   (South Korea)

Author keywords

Chitosan; Exenatide; Nanoparticle; PLGA

Indexed keywords

CHITOSAN; EXENDIN 4; NANOPARTICLE; POLYGLACTIN;

ARTICLE; DRUG STABILITY; MUCOADHESION; NANOENCAPSULATION; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SCANNING ELECTRON MICROSCOPY; ZETA POTENTIAL;

EID: 84888398943     PISSN: 20935552     EISSN: 20936214     Source Type: Journal    
DOI: 10.1007/s40005-013-0094-z     Document Type: Article

References (71)

1. Abismail B, Canselier JP, Wilhelm AM, Delmas H, Gourdon C (1999) Emulsification by ultrasound: drop size distribution and stability. Ultrason Sonochem 6: 75-83.
2. Aboubakar M, Puisieux F, Couvreur P, Vauthier C (1999) Physicochemical characterization of insulin-loaded poly(isobutylcyanoacrylate) nanocapsules obtained by interfacial polymerization. Int J Pharm 183(1): 63-66.
3. Adami RC, Collard WT, Gupta SA, Kwok KY, Bonadio J, Rice KG (1998) Stability of peptide-condensed plasmid DNA formulations. J Pharm Sci 87(6): 678-683.
4. Agnihotri SA, Mallikarjina NN, Aminabhavi TM (2004) Recent advances on chitosan-based micro- and nano-particles in drug delivery. J Control Release 100(1): 5-28.
5. Almeida A, Alpar HO, Brown RW (1993) Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(l-lactic acid) microspheres in rats, rabbits and guinea-pigs. J Pharm Pharmacol 43(3): 198-203.
6. Aubert-Pouessel A, Venier-Julienne MC, Saulnier P, Sergent M, Benoit JP (2004) Preparation of PLGA microparticles by an emulsion-extraction process using glycofurol as polymer solvent. Pharm Res 21(12): 2384-2391.
7. Azuaga AI, Dobson CM, Mateo PL, Conejero-Lara F (2002) Unfolding and aggregation during the thermal denaturation of streptokinase. Eur J Biochem 269(16): 4121-4133.
8. Bechtel S, Kielhorn-Bayer S, Mathauer K (1997) Vorrichtung zum Herstellen von dispersen Stoffgemischen mittels Ultraschall und Verwendung einer derartigen Vorrichtung. German Patent 197 56 874.
9. Bernkop-Schnurch A, Humenberger C, Valenta C (1998) Basic studies on bioadhesive delivery systems for peptide and protein drugs. Int J Pharm 165: 217-225.
10. Berthold K, Cremer J, Kreuter J (1996) Preparation and characterization of chitosan microspheres as drug carrier for prednisolone sodium phosphate as model for anti-inflammatory drugs. J Control Release 39(1): 17-25.
11. Bittner B, Witt C, Mader K, Kissel T (1999) Degradation and protein release properties of microspheres prepared from biodegradable poly(lactide-co-glycolide) and ABA triblock copolymers: influence of buffer media on polymer erosion and bovine serum albumin release. J Control Release 60(2-3): 297-309.
12. Bondy C, Sollner K (1935) On the mechanism of emulsification by ultrasonic waves. Trans Faraday Soc 31: 835-842.
13. Brange J, Andersen L, Laursen ED, Meyn G, Rasmussen E (1997) Toward understanding insulin fibrillation. J Pharm Sci 86(5): 517-525.
14. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD (2004) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27(11): 2628-2635.
15. Carino GP, Jacob JS, Mathiowitz E (2000) Nanosphere based oral insulin delivery. J Control Release 65(1-2): 261-269.
16. Cegnar M, Kos J, Kristl J (2004) Cystatin incorporated in poly(lactide-co-glycolide) nanoparticles: development and fundamental studies on preservation of its activity. Eur J Pharm Sci 22(5): 357-364.
17. Chen BL, Arakawa T, Hsu E, Narhi LO, Tressel TJ, Chien SL (1994) Strategies to suppress aggregation of recombinant keratinocyte growth-factor during liquid formulation development. J Pharm Sci 83(12): 1657-1661.
18. Chi EY, Krishnan S, Randolph TW, Carpenter JF (2003) Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 20(9): 1325-1336.
19. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28(5): 1092-1100.
20. Desai MP, Labhasetwar V, Amidon GL, Levy RJ (1996) Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 13(12): 1838-1845.
21. Dong Y, Feng SS (2004) Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 25(14): 2843-2849.
22. Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR (1990) Controlled vaccine release in the gut-associated lymphoid tissues. Orally administered biodegradable microspheres target the Peyer's patches. J Control Release 11(1-3): 205-214.
23. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP (1992) Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267(11): 7402-7405.
24. Fatouros A, Osterberg T, Mikaelsson M (1997) Recombinant factor VIII SQ-influence of oxygen, metal ions, ph and ionic strength on its stability in aqueous solution. Int J Pharm 155(1): 121-131.
25. Flory PJ (1953) Principles of polymer chemistry. Cornell University Press, New York, p 69.
26. Furman BL (2012) The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent. Toxicon 59(4): 467-471.
27. Gedulin BR, Smith PA, Jodka CM, Chen K, Bhavsar S, Nielsen LL, Parkes DG, Young AA (2008) Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. Int J Pharm 356(1-2): 231-238.
28. Heine RJ, van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG (2005) Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 143(8): 559-569.
29. Hu LD, Tang X, Cui D (2004) Solid lipid nano-particles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol 56(12): 1527-1535.
30. Ichikawa H, Peppas A (2003) Novel complexation hydrogels for oral peptide delivery: in vitro evaluation of their cytocompatibility and insulin-transport enhancing effects using Caco-2 cell monolayers. J Biomed Mater Res Part A 67(2): 609-617.
31. Ip AY, Arakawa T, Silvers H, Ransone CM, Niven RW (1995) Stability of recombinant consensus interferon to air-jet and ultrasonic nebulization. J Pharm Sci 84(10): 1210-1214.
32. Jani PU, Halbert GW, Langridge J, Florence AT (1989) The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J Pharm Pharmacol 41(12): 809-812.
33. Jani PU, McCarthy DE, Florence AT (1992) Nanospheres and microspheres uptake via Peyer's patches: observation of the rate of uptake in the rat after a single oral dose. Int J Pharm 86: 239-246.
34. Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JX, Kissel T (2000) Biodegradable nanoparticles for oral delivery of peptides: Is there a role for polymers to affect mucosal uptake? Eur J Pharm Sci 50(1): 147-160.
35. Katayama K, Koto Y, Onishi H, Nagai T, Mashida Y (2003) Double liposomes: hypoglycemic effects of liposomal insulin on normal rats. Drug Dev Ind Pharm 29(7): 725-731.
36. Kawashima Y, Yamamoto H, Takeuchi H, Kuno Y (2000) Mucoadhesive dl-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm Dev Technol 5(1): 77-85.
37. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28(5): 1083-1091.
38. Kerwin BA, Akers MJ, Apostol I, Moore-Einsel C, Etter JE, Hess E, Lippincott J, Levine J, Mathews AJ, Revilla- Sharp P, Schubert R, Looker DL (1999) Acute and long term stability studies of deoxy hemoglobin and characterization of ascorbate-induced modifications. J Pharm Sci 88(1): 79-88.
39. Kim A, Yun MO, Oh YK, Ahn WS, Kim CK (1999) Pharmacodynamics of insulin in polyethylene glycol-coated liposomes. Int J Pharm 180(1): 75-81.
40. Kostanski JW, DeLuca PP (2000) A novel in vitro release technique for peptide containing biodegradable microspheres. AAPS PharmSciTech 1(1): E4.
41. Li N, Zhuang C, Wang M, Sun X, Nie S, Pan W (2009) Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. Int J Pharm 379(1): 131-138.
42. Lin CR, Gokhale R, Trivedi JS, Ranada V (2004) Recent strategies and methods for improving insulin delivery. Drug Dev Res 63: 151-160.
43. Maa YF, Hsu CC (1999) Performance of sonication and microfluidization for liquid-liquid emulsification. Pharm Dev Technol 4: 233-240.
44. Malhotra M, Majumdar DK (2001) Permeation through cornea. Indian J Exp Biol 39(1): 11-24.
45. Maloy KJ, Donachie AM, Hagan DTO, Mowat M (1994) Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology 81(4): 661-667.
46. Manca ML, Mourtas S, Dracopoulos V, Fadda AM, Antimisiaris SG (2008) PLGA, chitosan or chitosan-coated PLGA microparticles for alveolar delivery? A comparative study of particle stability during nebulization. Colloids Surf B Biointerfaces 62(2): 220-231.
47. McClean S, Prosser E, Meehan E, O'Malley D, Clarke N, Ramtoola Z, Brayden D (1998) Binding and uptake of biodegradable poly-d, l-lactide micro and nanoparticles in intestinal epithelia. Eur J Pharm Sci 6(2): 153-163.
48. Medina J, Salvado A, del Pozo A (2001) Use of ultrasound to prepare lipid emulsions of lorazepam for intravenous injection. Int J Pharm 216: 1-8.
49. Nafee N, Taet S, Schneider M, Schaefer UF, Lehr CM (2007) Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine 3: 173-183.
50. Nauck MA (2004) Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Res 36(11-12): 852-858.
51. Nielsen LL (2005) Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov Today 10(10): 703-710.
52. Nielsen L, Khurana R, Coats A, Frokjaer S, Brange J, Vyas S, Uversky VN, Fink AL (2001) Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry 40(20): 6036-6046.
53. Pandit S, Martin C, Alpar HO (2005) Positively charged rifampicin-loaded microspheres for lung delivery. J Drug Deliv Sci Technol 15(4): 281-287.
54. Richards WT (1929) The chemical effects of high frequency sound waves: II. A study of emulsification action. J Am Chem Soc 51: 1724-1729.
55. Sabnis SS, Block LH (2000) Chitosan as an enabling excipient for drug delivery systems 1. Molecular modifications. Int J Biol Macromol 27(3): 181-186.
56. Sakuma S, Suzuki N, Sudo R, Hiwatari K, Kishida A, Akashi M (2002) Optimized chemical structure of nano-particles as carriers for oral delivery of salmon calcitonin. Int J Pharm 239(1-2): 185-195.
57. Shinha VR, Trehan A (2003) Biodegradable microspheres for protein delivery. J Control Release 90(3): 261-280.
58. Sigel H, Martin RB (1982) Coordinating properties of the amide bond. Stability and structure of metal ion complexes of peptides and related ligands. Chem Rev 82(4): 385-426.
59. Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima Y (1996) Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm Res 13(6): 896-901.
60. Takeuchi H, Yamamoto H, Kawashima Y (2001) Mucoadhesive nanoparticle systems for peptide drug delivery. Adv Drug Deliv Rev 47(1): 39-54.
61. Takeuchi H, Matsui Y, Yamamoto H, Kawashima Y (2003) Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J Control Release 86(2-3): 235-242.
62. Takeuchi H, Thongborisute J, Matsui Y, Sugihara H, Yamamoto H, Kawashima Y (2005) Novel mucoadhesion tests for polymers and polymer-coated particles to design optimal mucoadhesive drug delivery systems. Adv Drug Deliv Rev 57(11): 1583-1594.
63. Torres-Lugo M, Peppas A (2002) Preparation and characterization of P(MAA-g-EG) nanospheres for protein delivery applications. J Nanoparticle Res 4(1-2): 73-81.
64. Townsend MW, Deluca PP (1990) Stability of ribonuclease-a in solution and the freeze-dried state. J Pharm Sci 79(12): 1083-1086.
65. Tsai AM, van Zanten JH, Betenbaugh MJ (1998) II. Electrostatic effect in the aggregation of heat-denatured RNase and implications for protein additive design. Biotechnol Bioeng 59(3): 281-285.
66. van de Weert M, Hennink WE, Jiskoot W (2000) Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res 17(10): 1159-1167.
67. vander Merwe SM, Verhoef JC, Verheijden JHM, Kotze AF, Junginger HE (2004) Trimethylated chitosan as polymeric absorption enhancer for improved per oral delivery of peptide drugs. Eur J Pharm Biopharm 58(2): 225-235.
68. Vila A, Sanchez A, Tobio M, Calvo P, Alonso MJ (2002) Design of biodegradable particles for protein delivery. J Control Release 78(1-3): 15-24.
69. Walter E, Moelling K, Pavlovic J, Merkle HP (1999) Microencapsulation of DNA using poly(dl-lactide-co-glycolide): stability issues and release characteristics. J Control Release 61(3): 361-374.
70. Whitaker MJ, Hao M, Daives OR, Serhatkulu G, Stolnik-Trenkic S, Howdle SM, Shakesheff KM (2005) The production of protein-loaded microparticles by supercritical fluid enhanced mixing and spraying. J Control Release 101(1-3): 85-92.
71. Zhang X, Sun M, Zheng A, Cao D, Bi Y, Sun J (2012) Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration. Eur J Pharm Sci 45(5): 632-638.